Evaluating MBS314 for patients with relapsed or refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase I/II, multicenter, open-label study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MBS314, a novel asymmetric trivalent tri-specific humanized antibody, administered via intravenous infusion. The study is divided into two parts: a dose escalation phase (Phase Ia) and an expansion phase (Phase Ib/II). Participants must have a documented diagnosis of multiple myeloma and meet specific eligibility criteria to be included.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able and willing to provide written informed consent and to comply with the study protocol;
2. ≥18 years of age;
3. Documented diagnosis of multiple myeloma according to 2014 IMWG diagnostic criteria.
4. Phase Ⅰb/Ⅱ: At least one measurable disease: Serum monoclonal paraprotein (M-protein) ≥5 g/L or Urine M-protein ≥200 mg/24 hours or Serum immunoglobulin free-light chains (FLCs) ≥100 mg/L and abnormal kappa/lambda FLC ratio (\<0.26 or \>1.65)
5. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
6. Life expectancy ≥3 months.
7. Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

1. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
2. Participants with known active infection within 14 days prior to the first MBS314.
3. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (including HBsAg, HBcAb positive with abnormal hepatitis B virus DNA or hepatitis C virus RNA).
4. Previously received anti-myeloma treatment within the specified time frame prior to the first administration.
5. Live, attenuated vaccines within 28 days prior to the first infusion of MBS314, or expected to receive live, attenuated vaccines during the study period.
6. Major surgery within 28 days prior to the first infusion of MBS314, or expected to undergo major surgery during the study treatment.
7. Participants with a history of autoimmune diseases.
8. Known severe allergic reactions to other antibodies, or known allergies or hypersensitivity to any components of MBS314.

Where it's running

• Institute of Hematology and Blood Diseases Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Lugui Qiu, Doctor — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Lugui Qiu, Doctor
• Email: Qiulg@ihcams.ac.cn
• Phone: 0086-022-23608560

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AZD4045 in Relapsed or Refractory Multiple Myeloma

  This study tests AZD4045 alone and with daratumumab and aldesleukin in adults whose multiple myeloma has returned or stopped responding to treatment.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 11 other locations · NCT07681596

• A new treatment approach for relapsed or refractory multiple myeloma in adults

  This study tests if IBI3003 works better than the investigator's choice treatment for adults whose multiple myeloma has returned or persisted after prior therapy.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07623798

• O&D-001 CAR‑T injection for relapsed or refractory multiple myeloma

  This trial will test a CAR‑T injection called O&D‑001 that targets BCMA and GPRC5D in adults with relapsed or refractory multiple myeloma who have had at least two prior therapies.

  Recruiting Phase 1 O&D BioTech Group CO., Limited · Guangzhou, Guangdong · NCT07369895

• F182112 given with other drugs for relapsed or refractory multiple myeloma

  This trial will test whether F182112, given with different drug regimens, helps people whose multiple myeloma has returned or stopped responding to prior treatments.

  Recruiting Phase 2 Shandong New Time Pharmaceutical Co., LTD · Tianjin · NCT07312188

• QLS32015 versus pomalidomide+dexamethasone or selinexor+dexamethasone for relapsed or refractory multiple myeloma

  This will see if QLS32015 alone controls disease and is safe compared with pomalidomide+dexamethasone or selinexor+dexamethasone in adults with relapsed or refractory multiple myeloma who have had at least three prior treatments.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07138209

• mRNA-2808 for relapsed or refractory multiple myeloma

  This will test whether mRNA-2808 is safe and tolerable for people with relapsed or refractory multiple myeloma who have already received standard therapies.

  Recruiting at 10 sites Phase 1/2 ModernaTX, Inc. · Birmingham, Alabama and 9 other locations · NCT07116616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.